{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pharmacology:cilostazol",
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-05T15:00:00.000Z",
    "contributors": [
      "vascular-surgery-agent",
      "quality-enhancement-agent"
    ],
    "status": "peer-reviewed",
    "copyright_compliance": "Original content based on general medical knowledge",
    "modified": "2026-01-10T15:10:00.000Z",
    "confidence": 0.95
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "medication",
    "difficulty": "intermediate",
    "importance": "high",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Cilostazol",
    "definition": "Phosphodiesterase III inhibitor with vasodilatory, antiplatelet, and metabolic effects approved as first-line pharmacotherapy for intermittent claudication.",
    "mechanism_of_action": {
      "primary": "Selective phosphodiesterase III inhibition",
      "effects": [
        "Increased intracellular cAMP in platelets and vascular smooth muscle",
        "Vasodilation",
        "Inhibition of platelet aggregation",
        "Anti-proliferative effects on smooth muscle"
      ]
    },
    "indications": {
      "approved": "Intermittent claudication",
      "efficacy": "Improves maximal and pain-free walking distance by 40-60%"
    },
    "dosing": {
      "standard": "100 mg twice daily",
      "timing": "30 minutes before or 2 hours after meals",
      "reduced_dose": "50 mg BID with CYP3A4/CYP2C19 inhibitors"
    },
    "efficacy_data": {
      "walking_distance": "40-60% improvement in maximal walking distance",
      "vs_pentoxifylline": "Significantly more effective",
      "time_to_effect": "2-4 weeks for clinical benefit"
    },
    "contraindications": {
      "absolute": [
        "Heart failure (any severity)",
        "Previous hypersensitivity"
      ],
      "box_warning": "Class III antiarrhythmic effects, contraindicated in HF"
    },
    "side_effects": {
      "common": [
        "Headache (most common, ~30%)",
        "Diarrhea",
        "Palpitations",
        "Dizziness"
      ],
      "serious": "Cardiac arrhythmias (rare)"
    },
    "drug_interactions": {
      "cyp3a4_inhibitors": "Ketoconazole, erythromycin - reduce dose",
      "cyp2c19_inhibitors": "Omeprazole - reduce dose",
      "antiplatelet_agents": "Additive bleeding risk"
    },
    "clinical_positioning": {
      "first_line": "Preferred pharmacotherapy for claudication",
      "adjunctive": "With supervised exercise therapy"
    },
    "terminology": {
      "snomed_ct": "372658003",
      "icd_10": "Z79.02"
    },
    "statement": "Cilostazol is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Cilostazol helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Cilostazol include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Cilostazol."
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "pedagogical": {
    "learning_objectives": [
      "Describe cilostazol mechanism and efficacy",
      "Identify contraindication in heart failure",
      "Apply as first-line claudication therapy"
    ],
    "clinical_pearls": [
      "CONTRAINDICATED in heart failure - black box warning",
      "Headache is most common side effect (~30%)",
      "Takes 2-4 weeks for clinical benefit"
    ]
  },
  "relationships": {
    "broader": [
      "vascular:pharmacology:claudication-medications"
    ],
    "related": [
      "vascular:pharmacology:pentoxifylline",
      "vascular:pad:claudication"
    ],
    "narrower": [],
    "skos:broader": [
      "http://dbpedia.org/resource/Knowledge"
    ],
    "skos:related": [
      "http://dbpedia.org/resource/Concept"
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Cilostazol"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). Cilostazol. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "owl:sameAs": "http://dbpedia.org/resource/Cilostazol",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}